Mobia Medical, Inc.

What they do

Mobia Medical sells the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, an implanted pulse generator and lead that delivers vagus nerve stimulation during functional movement to improve upper limb function in chronic ischemic stroke survivors with moderate to severe impairments. The company markets primarily to stroke hospitals in the U.S., supported by Territory Managers and Therapy Development Specialists, and relies on third-party contract manufacturers.

Revenue drivers

• Vivistim System sales — The sole product line; revenue is driven by adoption at stroke centers and the number of implanted pulse generator (IPG) units sold.
• Stroke center adoption — Revenue growth tied to onboarding primary and comprehensive stroke centers; approximately 1,500 such centers in the U.S. and 70% of acute strokes seen at 900 hospitals.
• Therapy site network — Commercial strategy includes Therapy Development Specialists who educate therapy sites, facilitating patient referrals and sustained use of the system.

Recent performance

In Q2 2026, revenue was $13.5 million, up 102% year-over-year from $6.7 million, driven by higher adoption and more IPG units sold. Gross margin was 83.2%, up from 82.3%. Operating expenses rose 83% to $29.2 million, and net loss widened to $21.0 million ($1.10 per share) from $10.5 million ($12.44 per share) in Q2 2025. Cash and equivalents were $177.1 million as of June 30, 2026, including approximately $134.0 million in net IPO proceeds.

Strategy

Management plans to broaden its footprint and accelerate patient access to Vivistim Therapy, focusing on stroke centers as hubs for establishing self-sustaining care programs. The company emphasizes evidence-based adoption, with recent publication of two-year VNS-REHAB follow-up data in Neurology. It continues to expand its commercial organization, including personnel and commissions, and invest in development and general administrative capabilities.

Risks

• Dependence on single product — All revenue comes from the Vivistim System; any regulatory, clinical, or manufacturing setback would materially impact the business.
• Supply chain reliance — The company uses third-party contract manufacturers; disruptions, tariffs, or quality issues could raise costs or limit supply.
• Commercial adoption uncertainty — Revenue growth depends on continued adoption by stroke centers and therapy sites; slower-than-expected uptake would hurt results.
• Operating losses and negative cash flow — Despite high gross margins, operating expenses exceed revenue, leading to net losses; future profitability requires sustained growth and cost control.

Outlook

Management expects full-year 2026 revenue in the range of $54.0 million to $56.0 million, representing growth of 69% to 75% over 2025. The company plans to leverage IPO proceeds to broaden its footprint and accelerate patient access. The two-year durability data supports the clinical value proposition for ongoing adoption.